Biosensors gets DES (drug-eluting stent) study boost
This article was originally published in Clinica
Executive Summary
In what could intensify competition in the drug-eluting stent (DES) arena, Singapore firm Biosensors International has released positive results from a first-in-man trial of its BioMatrix device.